NETRIS Pharma

7 articles about NETRIS Pharma

• NETRIS Pharma Doses First Patient in Phase 2 Study of NP137 for Checkpoint Inhibitor Resistance

  11/29/2022

  NETRIS Pharma, a clinical-stage private biopharmaceutical company developing a new class of drugs based on dependence receptor biology, announced dosing of the first patient in the ImmunoNET trial.

• NETRIS Pharma, Orano and Centre Léon Bérard Announce Scientific Collaboration to Develop Novel Antibody Radio-Conjugate Therapies

  9/20/2022

  NETRIS Pharma SAS, a private clinical-stage biopharmaceutical company, announced that it has entered into a scientific collaboration agreement with Orano and the Centre Léon Bérard to develop novel Antibody Radio-Conjugates for the treatment of cancer.

• 

  BioSpace Global Roundup, May 7

  5/7/2020

  Pharma and life sciences companies from across the globe provide updates on their business and pipelines.

• NETRIS Pharma Announces Clinical Trial Collaboration Agreement with MSD to Evaluate NP137 in Combination with KEYTRUDA® (Pembrolizumab) in Advanced Uterine and Cervical Tumors

  5/5/2020

  Unique NP137 mechanism targeting netrin-1 could alleviate anti-PD-1 resistance

• NETRIS Pharma successfully completes first clinical study with first-in-class netrin-1 inhibitor NP137 in patients with advanced solid tumors

  12/12/2018

  NETRIS Pharma, a clinical-stage company developing novel anticancer therapies targeting dependence receptors, announced today successful completion of the first-in-human study on the effects of netrin-1 inhibition in patients with advanced solid tumors.

• LYONBIOPOLE Will Unite Leading French Biotech Actors at the 2018 BIO International Convention

  5/31/2018

  Lyonbiopole the French "bio-cluster" based in the Auvergne-Rhône-Alpes region, will unite 35 innovative organizations at the 2018 edition of the BIO International Convention.

• NETRIS Pharma Starts Enrollment Of First Clinical Study To Evaluate Drug Candidate Targeting Dependence Receptors

  3/21/2017